{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_181797.4:c.6056A>G",
          "cDNA Change": {
            "transcript": "NM_181797.4",
            "ref": "A",
            "alt": "G",
            "position": "6056"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S (p.G2019S)"
        }
      ]
    },
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000335.4:c.158C>T",
          "cDNA Change": {
            "transcript": "NM_000335.4",
            "ref": "C",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T (p.A53T)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0000001"
  },
  "Experiment Method": [
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Postmortem brain tissue",
        "Material Name": "PD patients with G2019S or A53T mutations",
        "Description": "Immunohistochemistry (IHC) and Western blot (WB) were performed to analyze LRRK2 and SNCA expression levels in brain tissues from PD patients with the G2019S and A53T mutations, respectively."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_181797.4:c.6056A>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Increased LRRK2 kinase activity and phosphorylation of downstream substrates (e.g., Rab10) were observed in G2019S carriers."
        },
        {
          "Variant": "NM_000335.4:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Elevated SNCA oligomerization and α-synuclein pathology were detected in A53T carriers."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2/SNCA overexpression was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Non-mutant brain tissue from healthy controls was used as a negative control."
      },
      "Statistical analysis": {
        "Statistical analysis": "ANOVA",
        "Description": "Statistical analysis was performed using ANOVA with post-hoc Tukey's test."
      },
      "Threshold for abnormality": {
        "Threshold for abnormality": "20% increase in LRRK2 kinase activity or 50% increase in SNCA oligomerization compared to controls."
      },
      "Approved assay": "Yes"
    },
    {
      "Assay Method": "Seahorse XF Analysis",
      "Material used": {
        "Material Source": "HEK293 cells",
        "Material Name": "HEK293 cells overexpressing LRRK2 G2019S",
        "Description": "Cell culture experiments using HEK293 cells overexpressing the LRRK2 G2019S mutant and wild-type LRRK2. Mitochondrial dysfunction was assessed using MitoTracker staining and Seahorse XF analysis."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_181797.4:c.6056A>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Mitochondrial respiration was reduced by 30% in G2019S-overexpressing cells compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was measured in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2-overexpressing cells were used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Non-transfected HEK293 cells were used as a negative control."
      },
      "Statistical analysis": {
        "Statistical analysis": "t-test",
        "Description": "Statistical analysis was performed using unpaired t-test."
      },
      "Threshold for abnormality": {
        "Threshold for abnormality": "20% decrease in mitochondrial respiration compared to controls."
      },
      "Approved assay": "Yes"
    },
    {
      "Assay Method": "Immunohistochemistry",
      "Material used": {
        "Material Source": "Postmortem brain tissue",
        "Material Name": "SNCA A53T carriers and controls",
        "Description": "Postmortem brain tissue analysis of SNCA A53T carriers and controls using immunohistochemistry to assess Lewy body pathology."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000335.4:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Increased Lewy body density and α-synuclein immunoreactivity were observed in A53T carriers."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Five biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "No",
        "Description": "No technical replicates were reported."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Brain tissue from A53T carriers with confirmed Lewy bodies was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Brain tissue from healthy controls without Lewy bodies was used as a negative control."
      },
      "Statistical analysis": {
        "Statistical analysis": "Chi-square test",
        "Description": "Statistical analysis was performed using chi-square test for categorical data."
      },
      "Threshold for abnormality": {
        "Threshold for abnormality": "Presence of Lewy bodies in >50% of neurons in A53T carriers."
      },
      "Approved assay": "Yes"
    }
  ]
}